Complement-SASP Amplification Cascade as Mechanistic Link

Target: C1QA, C1QB, C3, IL1B, NFKB1 Composite Score: 0.644 Price: $0.64▲1.5% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🔴 Alzheimer's Disease 🔥 Neuroinflammation 🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.644

Top 18% of 654 hypotheses

T5 Contested

Contradicted by evidence, under dispute

B+ Mech. Plausibility 15% 0.78 Top 39%

B Evidence Strength 15% 0.65 Top 46%

B+ Novelty 12% 0.75 Top 56%

C+ Feasibility 12% 0.55 Top 57%

A Impact 12% 0.80 Top 31%

B Druggability 10% 0.68 Top 45%

C Safety Profile 8% 0.42 Top 77%

B Competition 6% 0.62 Top 68%

B Data Availability 5% 0.60 Top 57%

B Reproducibility 5% 0.65 Top 45%

Evidence

5 supporting | 4 opposing

Citation quality: 0%

Debates

1 session B+

Avg quality: 0.75

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD pathogenesis?

The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design. Gap type: contradiction Source paper: Synergy between amyloid-β and tau in Alzheimer's disease. (2020, Nature neuroscience, PMID:32778792)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

TREM2 Agonism to Restore Microglial Phagocytosis Across Both Pathologies

Score: 0.638 | Target: TREM2, TYROBP (DAP12), PLCG2, SYK

→ View full analysis & all 2 hypotheses

Description

Senescent microglia release SASP factors that amplify complement cascade activation (C1Q, C3), driving excessive synaptic pruning. This creates a feedforward loop where Aβ drives senescence, SASP amplifies complement, and complement accelerates tau pathology. Targeting this axis prevents synaptic loss and tau propagation that continue even after Aβ reduction.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

9 citations 9 with PMID Validation: 0% 5 supporting / 4 opposing

✓ For (5)

No supporting evidence

No opposing evidence

(4) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 7CLIN 2GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Young adult microglial deletion of C1Q reduces syn…	Supporting	MECH	-	-	-	-	PMID:41000995	-
SASP-mediated mechanisms drive neuroinflammation i…	Supporting	MECH	-	-	-	-	PMID:37814508	-
Complement plays a role in synaptic pruning and ne…	Supporting	MECH	-	-	-	-	PMID:34595138	-
SASP exacerbates synaptic remodeling in tauopathy	Supporting	MECH	-	-	-	-	PMID:36906076	-
ANX005 (Annexon) anti-C1Q antibody completed Phase…	Supporting	CLIN	-	-	-	-	PMID:29202623	-
Anti-C1q antibodies have been tested in other indi…	Opposing	MECH	-	-	-	-	PMID:NOCITE	-
SASP composition varies by cell type, senescence i…	Opposing	MECH	-	-	-	-	PMID:NOCITE	-
Complement-mediated synaptic loss may occur predom…	Opposing	CLIN	-	-	-	-	PMID:NOCITE	-
Blocking C1Q may prevent pathological synapse loss…	Opposing	MECH	-	-	-	-	PMID:41000995	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 5

Young adult microglial deletion of C1Q reduces synapse engulfment and prevents cognitive impairment

PMID:41000995

SASP-mediated mechanisms drive neuroinflammation in AD

PMID:37814508

Complement plays a role in synaptic pruning and neurodegeneration

PMID:34595138

SASP exacerbates synaptic remodeling in tauopathy

PMID:36906076

ANX005 (Annexon) anti-C1Q antibody completed Phase 1 in non-neurological indications

PMID:29202623

✗ Opposing Evidence 4

Anti-C1q antibodies have been tested in other indications with significant infection risk

PMID:NOCITE

SASP composition varies by cell type, senescence inducer, and microenvironment - oversimplification risk

PMID:NOCITE

Complement-mediated synaptic loss may occur predominantly during development or early disease stages - late-st…▼

Complement-mediated synaptic loss may occur predominantly during development or early disease stages - late-stage intervention may be too late

PMID:NOCITE

Blocking C1Q may prevent pathological synapse loss but could also impair developmental pruning and adult plast…▼

Blocking C1Q may prevent pathological synapse loss but could also impair developmental pruning and adult plasticity

PMID:41000995

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-16 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

The user wants me to generate 4-5 mechanistically specific hypotheses about Aβ-tau synergy in Alzheimer's disease, specifically addressing the contradiction that anti-Aβ trials have failed despite Aβ being considered the initiating pathology. This is a gap-type "contradiction" analysis, meaning there's a discrepancy between expected outcomes and actual results.

Key context:

Anti-Aβ therapies have failed in clinical trials
Aβ-tau synergy could explain these failures
Existing hypotheses to build upon:

1. Complement-SASP Amplification Cascade (score 0.61)

TREM2 Agonism to restore mi

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Assessment: Aβ-Tau Synergy Hypotheses

Executive Summary

The translational landscape for Aβ-tau synergy hypotheses is increasingly tractable given recent trial failures and biomarker validation. I'll identify high-potential hypotheses, address feasibility constraints, and propose mechanistic refinements.

1. Top 3 Hypotheses by Translational Potential

Hypothesis A: Tau Dendritic Missorting as Gain-of-Toxic-Function (Highest Potential)

Core Mechanism:
Aβ triggers tau hyperphosphorylation and missorting from axons to dendrites, where it enhances NMDA recep

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Price History

7d Trend

↗

Rising

7d Momentum

▲ 1.4%

Volatility

High

0.0648

Events (7d)

⚡ Price Movement Log Recent 3 events

	Event	Price	Change	Source	Time
📄	New Evidence	$0.614	▼ 9.0%	market_dynamics	2026-04-17 06:26
💬	Debate Round	$0.675	▲ 2.9%	market_dynamics	2026-04-17 02:17
📊	Score Update	$0.655		market_dynamics	2026-04-17 01:43